Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Influenza B strain confirmed

Executive Summary

FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...

You may also be interested in...

Reverse Genetics Is Best Path To Cell Culture Vaccines – FDA Committee

Reverse genetics holds the greatest promise for developing cell culture-based vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Feb. 19

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts